Clinical Research Directory
Browse clinical research sites, groups, and studies.
Senolytics for Secondary Progressive MS
Sponsor: Ohio State University
Summary
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
Official title: Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-01-15
Completion Date
2028-01-15
Last Updated
2025-12-08
Healthy Volunteers
No
Interventions
Dasatinib and quercetin
Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks
Locations (1)
Ohio State Martha Morehouse Outpatient Care
Columbus, Ohio, United States